You are here

ImmPACT Bio

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Biopharma Reporter

Thu, 08/22/24 - 11:15 am

multiple sclerosis

clinical trials

ImmPACT Bio reels in $111M to prevent tumor escape with novel cell therapies

MedCity News

Thu, 01/20/22 - 11:20 pm